{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ05145",
      "entity_text" : "SRT501",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q96EB6",
      "entity_text" : "SIRT1",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In this report we characterize the early molecular signaling events that are shared between treatment with two structurally distinct SIRT1 activating compounds, SRT501, a proprietary formulation of resveratrol with enhanced pharmacokinetic properties and improved oral bioavailability, and SRT1720, a chemically distinct compound with nanomolar potency toward SIRT1 [XREF_BIBR].",
  "reading_complete" : "2020-08-03T19:54:25Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T19:48:20Z",
  "trigger" : "activating",
  "evidence" : [ "SIRT1 activating compounds, SRT501" ],
  "pmc_id" : "2660283",
  "score" : 0
}